BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Wound Management Technologies, Inc. Enters Into a Distribution Agreement with an Initial $2M Order for CellerateRX(R)


8/23/2011 11:28:04 AM

FORT WORTH, Texas, Aug. 22, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced a major distribution deal with Marketing Media Enterprises, LLC (MME), an Orlando Florida medical products distributor serving the direct-to-consumer and military market. The initial $2M order from MME is the first of what are expected to be recurring orders to supply its merchant customer base, and MME has agreed to prominently feature CellerateRX® within its direct-to-consumer sales channels.

Scott Haire, Chairman & CEO of Wound Management Technologies said, "Our management team has built a public company consisting of innovative medical products. While a portion of our larger sales have been pushed into the second half of this year, the MME agreement allows the Company to reiterate its minimum $6M 2011 full-year sales projection. Additionally, the Company expects sales to accelerate into the 2012 fiscal year."

Mr. Haire further commented, "This is just the beginning of the broadening of our sales channels. As Wound Management's presence grows in the media space, MME should be able to increase product sales through not only television markets but radio as well. The agreement facilitates the growth of revenues without having the large sales force most companies require to gain market share in the wound care space. The Company's goal is to have a consistent and predictable flow of sales through a distribution network, and this agreement is a major step in that direction."

According to Deborah Jenkins Hutchinson, President of Wound Management Technologies: "The need for effective wound care treatment has never been greater, as our population ages and type 2 diabetes affects more and more Americans. In light of these statistics, the Company has positioned CellerateRX® to be a leading wound care product within many different sales channels. Today's agreement portends a major penetration in the consumer markets for CellerateRX®. Wound Management looks forward to supplying MME's growing consumer base."

CellerateRX® Activated Collagen is the Differentiator

CellerateRX®'s activated collagen (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to prepare the collagen for use in the wound healing process. In people with compromised health or circulation, the difference in wound healing can be significant.

CellerateRX® is FDA cleared for all wound types except for 3rd degree burns and is available in both powder and gel form. In addition to being used in healthcare settings throughout the country, CellerateRX® is easily applied by patients by themselves at home. CellerateRX® is safe, non-toxic, and easy to use. More information can be found at www.CellerateRX.com

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.

Follow us on:FACEBOOK | TWITTER | LINKEDIN

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com

SOURCE Wound Management Technologies, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES